title: Injection of plasmin in local area: a new treatment option for nasal polypsis.
abstract: Nasal polypsis(NP), is one of the most difficult challenges in otorhinolaryngology, as the aetiology and pathophysiology are largely unknown unfortunately, medical treatment is unsatisfactory, and, because of frequent recurrences, repeated surgical interventions are often necessary. Now in clinic, the therapy for NP involves a combination of observation, medical, and surgical treatments. But with both treatments of medical and surgical, recurrences are still common. In nasal polypsis, although fibrotic changes do not dominate, myofibroblasts are significantly more abundant in the pedicle where the polyps can be thought to "grow" than in the central or tip areas. But in the "health" nasal mucosa, myofibroblasts can not been observed. Under normal conditions, when the injury is recovery, myofibroblats subsequent disappear from the injured site due to apoptosis. It is very interesting that myofibroblasts can survival in nasal polyps. We hypothesize here that, in nasal polyps, myofibroblasts adopt strategies to avoid apoptosis and consequent clearance by the immune system. In the "grow" area where the conditions are unchecked, deranged or repeated tissue repair, myofibroblasts, as the key factors, push about the formation or growth of the nasal polyps. So we try injecting plasmin in the pedicle of nasal polypsis to promote myofibroblast apoptosis, which may lead to a new treatment option for this incapacitating disease.
authors.affiliation: Department of Otorhinolaryngology, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Li
authors.forename: Shixi
authors.initials: S
authors.lastname: Liu
mesh_terms: D000281:Administration, Intranasal; D005341:Fibrinolysin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008962:Models, Theoretical; D009298:Nasal Polyps / Q000188:drug therapy*
chemical_list: D005341:Fibrinolysin